注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Oncternal Therapeutics Inc是一家临床阶段的生物制药公司。该公司专注于开发肿瘤疗法,用于治疗具有严重未满足医疗需求的癌症患者。该公司的候选产品包括Zilovertamab、ONCT-808、ONCT-534和ONCT-216。Zilovertamab是一种研究性人源化单克隆抗体,旨在抑制受体酪氨酸激酶样孤儿受体1(ROR1),这是一种在许多肿瘤上表达的生长因子受体,可激活增加肿瘤增殖、侵袭性和耐药性的途径,并结合到ROR1的特定功能重要表位。ONCT-808是一种靶向ROR1的自体嵌合抗原受体(CAR-T)疗法,用于治疗血液系统恶性肿瘤和实体瘤。ONCT-534是一种双重作用雄激素受体抑制剂(DAARI),用于治疗晚期去势抵抗性前列腺癌(CRPC)和其他雄激素受体(AR)驱动的疾病。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
David F. Hale | 75 | 2019 | Independent Chairman of the Board |
Daniel L. Kisner | 77 | 2019 | Independent Director |
Thomas Kipps | - | - | Scientific Advisor |
Robert James Wills | 70 | 2019 | Non-Independent Director |
Xin Nakanishi | 62 | 2019 | Independent Director |
Gunnar F. Kaufmann | 47 | 2019 | Prostate Cancer & Cell Therapy Scientific Advisory Board Member |
Charles P. Theuer | 60 | 2019 | Independent Director |
James B. Breitmeyer | 70 | 2019 | President, CEO & Director |
Michael G. Carter | 86 | 2006 | Independent Director |
William R. LaRue | 73 | 2019 | Independent Director |
Angela Shen | - | 2021 | Cell Therapy Scientific Advisory Board Member |
Jill M. DeSimone | 68 | 2023 | Independent Director |
Rosemary Mazanet | 68 | 2021 | Independent Director |
Sadik Kassim | 43 | 2021 | Cell Therapy Scientific Advisory Board Member |
Michael Wang | - | 2021 | Cell Therapy Scientific Advisory Board Member |
Johann De Bono | - | 2023 | Prostate Cancer Scientific Advisory Board Member |
Marcela V. Maus | 47 | 2021 | Cell Therapy Scientific Advisory Board Member |
Evan Ya-Wen Yu | - | 2023 | Prostate Cancer Scientific Advisory Board Member |
Matthew R. Smith | - | 2023 | Prostate Cancer Scientific Advisory Board Member |
Howard R. Soule | - | 2023 | Prostate Cancer Scientific Advisory Board Member |
Scott Dehm | - | 2023 | Prostate Cancer Scientific Advisory Board Member |
Ramesh Narayanan | - | 2023 | Scientific Advisors |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核